Novartis has filed an appeal at the Supreme Court (India’s Highest Court) challenging the refusal of its patent application for its blood cancer drug Glivec by the Intellectual Property Appellate Board (IPAB- India’s IP tribunal).

The IPAB in its decision in July had rejected Novartis’s appeal against refusal of its Patent Application for its drug Glivec by the Indian Patent Office (Chennai) back in January 2006 on grounds that the application was not patentable under Section 3(b) (Public order, since the drug was high priced) and 3(d) (failing to give a significantly enhanced efficacy) of the Indian Patent Act.

Read more on Mint, Hindu, Times of India reports on this. SpicyIP has been covering this matter from day one, read them here